PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
0.8190
-0.0290 (-3.42%)
At close: Jan 30, 2026, 4:00 PM EST
0.8400
+0.0210 (2.56%)
After-hours: Jan 30, 2026, 6:35 PM EST

PharmaCyte Biotech Income Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '25 Apr '25 Apr '24 Apr '23 Apr '22 Apr '21
Selling, General & Admin
3.753.946.115.993.72.71
Research & Development
0.480.440.410.470.690.92
Operating Expenses
4.234.386.526.464.393.62
Operating Income
-4.23-4.38-6.52-6.46-4.39-3.62
Interest Expense
-----0-0
Interest & Investment Income
0.911.423.41.940.16-
Other Non Operating Income (Expenses)
-7.239.115.450.2-0-0
EBT Excluding Unusual Items
-10.556.152.33-4.32-4.24-3.63
Gain (Loss) on Sale of Investments
5.3826.53----
Asset Writedown
---2---
Legal Settlements
-1.91-2.02----
Other Unusual Items
-----0.08
Pretax Income
-7.0730.660.33-4.32-4.24-3.55
Net Income
-7.0730.660.33-4.32-4.24-3.55
Preferred Dividends & Other Adjustments
0.567.2917.57---
Net Income to Common
-7.6323.36-17.24-4.32-4.24-3.55
Net Income Growth
-9084.98%----
Shares Outstanding (Basic)
771019161
Shares Outstanding (Diluted)
771019161
Shares Change (YoY)
-15.57%-23.50%-50.84%25.56%971.73%60.24%
EPS (Basic)
-1.113.19-1.80-0.22-0.27-2.45
EPS (Diluted)
-1.113.19-1.80-0.22-0.27-2.45
EBIT
-4.23-4.38-6.52-6.46-4.39-3.62
Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q